抄録
Background: TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders. Patients and Methods: Background, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed. Results: Forty-three patients, including fragile patients due to declining performance status and other comorbidities (37%) were analyzed. Efficacy was reflected in an objective overall response of 3%, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%). Febrile neutropenia was found in 7%. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102. Conclusion: TAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.
| 元の言語 | 英語 |
|---|---|
| ページ（範囲） | 1959-1966 |
| ページ数 | 8 |
| ジャーナル | Anticancer Research |
| 巻 | 36 |
| 発行部数 | 4 |
| 出版物ステータス | 出版済み - 4 1 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
これを引用
Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer. / Arita, Shuji; Shirakawa, Tsuyoshi; Matsushita, Yuzo; Shimokawa, Hozumi Kumagai; Hirano, Gen; Makiyama, Akitaka; Shibata, Yoshihiro; Tamura, Shingo; Esaki, Taito; Mitsugi, Kenji; ariyama, hiroshi; Kusaba, Hitoshi; Akashi, Koichi; Baba, Eishi.
：: Anticancer Research, 巻 36, 番号 4, 01.04.2016, p. 1959-1966.研究成果: ジャーナルへの寄稿 › 記事
}
TY - JOUR
T1 - Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer
AU - Arita, Shuji
AU - Shirakawa, Tsuyoshi
AU - Matsushita, Yuzo
AU - Shimokawa, Hozumi Kumagai
AU - Hirano, Gen
AU - Makiyama, Akitaka
AU - Shibata, Yoshihiro
AU - Tamura, Shingo
AU - Esaki, Taito
AU - Mitsugi, Kenji
AU - ariyama, hiroshi
AU - Kusaba, Hitoshi
AU - Akashi, Koichi
AU - Baba, Eishi
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Background: TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders. Patients and Methods: Background, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed. Results: Forty-three patients, including fragile patients due to declining performance status and other comorbidities (37%) were analyzed. Efficacy was reflected in an objective overall response of 3%, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%). Febrile neutropenia was found in 7%. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102. Conclusion: TAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.
AB - Background: TAS-102 is an anti-metabolite which demonstrated activity against multidrug-resistant advanced colorectal cancer. Its major toxicities are hematological disorders. Patients and Methods: Background, TAS-102 efficacy, toxicities and outcomes for patients with multidrug-resistant advanced colorectal cancer from six Institutions of the Kyushu Medical Oncology Group were retrospectively surveyed. Results: Forty-three patients, including fragile patients due to declining performance status and other comorbidities (37%) were analyzed. Efficacy was reflected in an objective overall response of 3%, median progression-free survival of 74 days (2.5 months) and median overall survival of 229 days (7.6 months). The most frequent Common Terminology Criteria for Adverse Events grade 3/4 adverse events were neutropenia (44%), leukopenia (26%) and anemia (23%). Febrile neutropenia was found in 7%. Sub-group analysis demonstrated an improved outcome on treatment with the sequence regorafenib-TAS-102. Conclusion: TAS-102 was safely administered to modestly fragile patients with equivalent efficacy to that for the non-fragile population. Further investigation of sequential treatment using regorafenib and TAS-102 is needed.
UR - http://www.scopus.com/inward/record.url?scp=84984576826&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984576826&partnerID=8YFLogxK
M3 - Article
VL - 36
SP - 1959
EP - 1966
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 4
ER -